SPRO
Spero Therapeutics, Inc. NASDAQ Listed Nov 2, 2017$2.28
+8.06%
vs $2.11
Mkt Cap $134.6M
52w Low $1.83
37.2% of range
52w High $3.04
50d MA $2.68
200d MA $2.40
P/E (TTM)
15.2x
EV/EBITDA
—
P/B
2.2x
Debt/Equity
0.1x
ROE
14.5%
P/FCF
-10.7x
RSI (14)
36.20
ATR (14)
$0.26
Beta
1.45
50d MA
$2.68
200d MA
$2.40
Avg Volume
1.4M
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
675 Massachusetts Avenue · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | AMC | -0.18 | -0.13 | +27.8% | 2.44 | +0.0% | +13.1% | +1.1% | -7.5% | +0.4% | +1.5% | — |
| Mar 26, 2026 | AMC | -0.20 | 0.53 | +365.0% | 2.37 | -3.0% | -1.7% | -3.9% | +4.5% | +4.7% | -0.8% | — |
| Nov 13, 2025 | AMC | -0.25 | -0.13 | +48.0% | 2.44 | -2.0% | -1.2% | +0.8% | +1.6% | -3.6% | -5.0% | — |
| Aug 12, 2025 | AMC | -0.38 | -0.03 | +92.1% | 2.36 | -8.9% | -17.8% | +2.1% | -3.5% | +0.0% | -3.7% | — |
| May 13, 2025 | AMC | -0.55 | -0.25 | +54.5% | 0.69 | +1.4% | -5.8% | +0.2% | -0.0% | +5.9% | -1.3% | — |
| Mar 27, 2025 | AMC | -0.35 | -0.38 | -8.6% | 0.86 | -1.2% | -10.9% | -6.1% | -3.6% | +1.7% | -11.6% | — |
| Nov 14, 2024 | AMC | -0.27 | -0.32 | -18.5% | 1.25 | +0.0% | -5.6% | -3.4% | +1.8% | +3.4% | -0.8% | — |
| Aug 5, 2024 | AMC | -0.35 | -0.33 | +5.7% | 1.34 | +3.0% | -5.2% | -3.1% | +2.4% | +1.6% | +0.8% | — |
| May 15, 2024 | AMC | -0.07 | -0.24 | -242.9% | 1.62 | -1.2% | -3.1% | +1.3% | -1.9% | -3.2% | +0.0% | — |
| Mar 13, 2024 | AMC | -0.10 | 0.96 | +1060.0% | 1.66 | +10.2% | +4.8% | +2.9% | -3.4% | +2.9% | -1.1% | — |
| Nov 13, 2023 | AMC | -0.15 | 0.02 | +113.3% | 1.11 | +2.7% | -1.8% | +4.6% | +1.8% | +2.6% | +3.4% | — |
| Aug 10, 2023 | AMC | -0.29 | -0.23 | +20.7% | 1.45 | +1.4% | -3.4% | -2.1% | -1.5% | -3.0% | +2.3% | — |
| May 11, 2023 | AMC | -0.35 | -0.25 | +28.6% | 1.92 | -1.0% | -3.6% | +1.1% | -4.3% | +1.7% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.2% | +1.2% | -1.5% | -6.3% | -6.2% | +16.4% |
| Dec 20 | Evercore ISI | Downgrade | Outperform → In Line | — | $1.00 | $0.99 | -0.8% | -4.3% | -3.4% | +1.6% | +0.7% | +9.1% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.14 | $1.13 | -0.9% | -0.9% | +2.7% | +1.7% | -1.7% | +0.9% |
| Nov 18 | TD Cowen | Downgrade | Buy → Hold | — | $1.18 | $1.20 | +1.7% | -3.4% | +1.8% | +3.4% | -0.8% | -2.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.18 | $1.16 | -1.7% | +9.3% | +1.6% | +0.0% | +0.0% | +0.8% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | -1.5% | +0.8% | +0.0% | -4.6% | +0.0% |
| Aug 6 | TD Cowen | Upgrade | Hold → Buy | — | $1.34 | $1.38 | +3.0% | -5.2% | -3.1% | +2.4% | +1.6% | +0.8% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.34 | $1.38 | +3.0% | -5.2% | -3.1% | +2.4% | +1.6% | +0.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.62 | $1.60 | -1.2% | -3.1% | +1.3% | -1.9% | -3.2% | +0.0% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.70 | -5.0% | -3.4% | +2.9% | -1.1% | -1.7% | +1.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.11 | $1.14 | +2.7% | -1.8% | +4.6% | +1.8% | +2.6% | +3.4% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.52 | +0.0% | -5.9% | -3.5% | -2.9% | +1.5% | -2.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.41 | +0.7% | -2.1% | -1.5% | -3.0% | +2.3% | -4.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.62 | -0.6% | -6.7% | +1.3% | -1.9% | +0.0% | -0.7% |
| Jul 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | -1.4% | -0.7% | +0.0% | -2.8% | +0.7% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | +3.3% | +3.8% | +0.0% | +5.6% | +0.6% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.00 | +1.5% | +6.1% | -3.3% | +1.5% | -3.9% | +1.5% |
| Sep 23 | Evercore ISI | Upgrade | In Line → Outperform | — | $2.20 | $2.27 | +3.2% | -10.5% | +6.1% | -3.3% | +1.5% | -3.9% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.78 | $0.78 | +0.0% | +15.9% | -0.9% | +19.4% | -3.7% | -4.6% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.37 | -0.7% | -3.6% | -7.5% | -2.4% | +0.0% | +3.3% |
| May 20 | Berenberg | Downgrade | Buy → Hold | — | $1.44 | $1.41 | -2.1% | -4.2% | -3.6% | -7.5% | -2.4% | +0.0% |
| May 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.71 | $1.77 | +3.5% | -3.5% | -12.7% | +0.0% | -4.2% | -3.6% |
| May 4 | Evercore ISI | Downgrade | Outperform → In Line | — | $1.85 | $1.62 | -12.4% | -5.4% | +5.1% | +12.5% | -8.7% | -6.9% |
| May 4 | TD Cowen | Downgrade | Outperform → Market Perform | — | $1.85 | $1.62 | -12.4% | -5.4% | +5.1% | +12.5% | -8.7% | -6.9% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.11 | $6.02 | -1.5% | -6.9% | +4.6% | -0.8% | -7.3% | +0.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.38 | $8.72 | +4.1% | +1.7% | +1.5% | -2.4% | -0.5% | -3.0% |
| Oct 1 | Oppenheimer | Downgrade | Outperform → Perform | — | $18.41 | $17.57 | -4.6% | -4.7% | +3.0% | +3.8% | -7.8% | -1.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.75 | $18.65 | +5.1% | +5.9% | +0.9% | -1.6% | -3.6% | +1.2% |
| Dec 16 | Berenberg | Maintains | Buy → Buy | — | $17.40 | $17.87 | +2.7% | +5.5% | +0.9% | -4.5% | +7.3% | +14.5% |
| Nov 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.18 | $15.86 | +4.5% | +4.7% | +0.0% | +0.1% | +5.1% | -1.0% |
| Sep 29 | Evercore ISI | Maintains | Outperform → Outperform | — | $9.30 | $10.22 | +9.9% | +7.0% | +12.2% | +4.4% | +3.5% | +3.3% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.78 | $11.85 | +0.6% | +8.2% | -5.9% | -2.5% | +0.0% | +2.0% |
| Mar 17 | Stifel | Maintains | Buy → Buy | — | $5.27 | $5.60 | +6.3% | +28.8% | -8.8% | +5.8% | -11.3% | +2.1% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.71 | $10.88 | +1.6% | -2.0% | +1.9% | -1.2% | -0.4% | -0.4% |
| Nov 5 | H.C. Wainwright | Maintains | Buy → Buy | — | $10.71 | $10.88 | +1.6% | -2.0% | +1.9% | -1.2% | -0.4% | -0.4% |
| Sep 9 | Janney Capital | Maintains | Buy → Buy | — | $9.98 | $10.74 | +7.6% | +11.2% | +5.9% | +6.8% | -0.9% | -4.0% |
| Oct 16 | BofA Securities | Downgrade | Neutral → Underperform | — | $9.76 | $9.33 | -4.4% | -12.8% | +0.9% | -0.6% | -0.2% | -1.3% |
| May 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $11.59 | $12.58 | +8.5% | +3.9% | -5.2% | +7.2% | -1.1% | +0.4% |
| Feb 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.97 | $12.08 | +0.9% | -0.8% | -2.7% | -3.1% | -10.7% | -0.4% |
| Nov 27 | Stifel | Maintains | Buy → Buy | — | $13.86 | $14.26 | +2.9% | +1.5% | -3.1% | -6.2% | -6.5% | +1.6% |
| Nov 27 | TD Cowen | Maintains | Outperform → Outperform | — | $13.86 | $14.26 | +2.9% | +1.5% | -3.1% | -6.2% | -6.5% | +1.6% |
| Nov 27 | BofA Securities | Maintains | Neutral → Neutral | — | $13.86 | $14.26 | +2.9% | +1.5% | -3.1% | -6.2% | -6.5% | +1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Rajavelu Esther | See Remarks | Sell | 25,240 | $2.51 | $63K | 986,851 | -0.79% | -3.94% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Gsk Plc | 9,190,606 | $22M | — | Mar 2026 |
| 2 | Pfizer Inc | 2,362,348 | $6M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,799,880 | $4M | New | Mar 2026 |
| 4 | Renaissance Technologies Llc | 1,189,235 | $3M | Reduced | Mar 2026 |
| 5 | Alphabet Inc. | 889,979 | $2M | — | Dec 2025 |
| 6 | Two Sigma Investments, Lp | 885,631 | $2M | Added | Mar 2026 |
| 7 | Anson Funds Management Lp | 843,912 | $2M | Reduced | Mar 2026 |
| 8 | Citadel Advisors Llc | 376,458 | $881K | Reduced | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 333,115 | $779K | Added | Mar 2026 |
| 10 | Ionic Capital Management Llc | 195,939 | $458K | — | Mar 2026 |
| 11 | Jane Street Group, Llc | 158,344 | $369K | Added | Dec 2025 |
| 12 | Marshall Wace, Llp | 157,072 | $368K | New | Mar 2026 |
| 13 | Northern Trust Corp | 120,984 | $283K | — | Mar 2026 |
| 14 | Point72 Asset Management | 59,668 | $140K | Added | Mar 2026 |
| 15 | Invesco Ltd. | 45,374 | $106K | Added | Mar 2026 |
| 16 | Quadrature Capital Ltd | 40,128 | $94K | Added | Mar 2026 |
| 17 | Capital Asset Advisory Services Llc | 32,548 | $92K | — | Mar 2026 |
| 18 | Verdad Advisers, Lp | 33,455 | $78K | New | Mar 2026 |
| 19 | Axxcess Wealth Management, Llc | 32,548 | $76K | — | Dec 2025 |
| 20 | Simplex Trading, Llc | 30,304 | $71K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$134.6M
Enterprise Value
$94.3M
P/E (TTM)
15.20x
Forward P/E
3.40x
PEG Ratio
-0.14x
P/B
2.16x
P/S
2.26x
P/FCF
-10.66x
EV/EBITDA
—
Shares Out
59.0M
Financials (TTM)
Revenue
$59.6M
Net Income
$8.6M
EBITDA
-$24K
Free Cash Flow
-$12.6M
Op Cash Flow
-$12.6M
EPS Basic
$0.15
EPS Diluted
$0.15
EPS Forward
$0.67
Gross Margin
100.0%
Op Margin
-0.0%
Net Margin
14.4%
Balance Sheet
Total Assets
$68.9M
Total Liab.
$9.9M
Total Equity
$59.0M
Cash
$40.3M
LT Debt
$0
Book Value/Sh
$1.05
Debt/Equity
0.05x
Current Ratio
7.59
Quick Ratio
7.59
Returns & Growth
ROE
14.5%
ROA
12.4%
ROIC
-0.0%
Rev Growth YoY
+24.3%
EPS Growth YoY
+111.8%
Price Returns
2W
+2.5%
1M
+12.7%
3M
+30.4%
6M
+17.9%
12M
+13.2%
Technicals
52W High
$3.04
52W Low
$1.83
50d MA
$2.68
200d MA
$2.40
RSI (14)
36.20
ATR (14)
$0.26
Beta
1.45
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 2:39am
· Source: financialmodelingprep.com